Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics, Inc. appointed Joel Sendek as its new Chief Financial Officer and principal financial officer, effective September 4, 2025, replacing Juan Graham in the CFO role. The company detailed Mr. Sendek’s background, compensation, equity incentives, and severance protections in his employment agreement.
Mr. Sendek will receive a $500,000 annual base salary, a target annual bonus equal to 40% of base salary, and a one-time option grant to purchase 600,000 shares of common stock, vesting over four years. The agreement also provides 12 months of salary, bonus-related amounts, COBRA premiums, and accelerated vesting of equity awards under certain termination and change-in-control conditions, subject to a release of claims.
Perspective Therapeutics, Inc. reported that its Board of Directors voted to increase the board size from five to six members and appointed Maya Martinez-Davis as a director, effective September 3, 2025. She will also serve on the Compensation Committee and the Nominations and Corporate Governance Committee.
Under the company’s Non-Employee Director Compensation Program, Ms. Martinez-Davis will receive an annual cash retainer of $60,000 and an initial grant of 75,000 stock options, with the grant date fair value capped at $450,000. These options vest in 36 equal monthly installments starting one month after the grant date, contingent on her continued service. The company expects her to enter into its standard indemnification agreement, and it states there are no related-party transactions requiring disclosure. A press release announcing her appointment was issued on September 3, 2025 and furnished as Exhibit 99.1.
Perspective Therapeutics, Inc. filed a current report to note that on September 2, 2025, the company updated its corporate presentation. The updated presentation is included as Exhibit 99.1 and is incorporated by reference into the disclosure. This type of presentation typically provides an overview of the business and strategy for investors, but the specific contents are not detailed here.
Perspective Therapeutics, Inc. is a radiopharmaceutical developer focused on targeted alpha therapies. At June 30, 2025 the company reported $28.85 million in cash and $162.73 million in short-term investments (combined $191.6 million), and management believes these resources will fund current planned operations into late 2026.
Operating spending rose notably year-over-year as R&D increased to $30.95 million for the six months ended June 30, 2025 and total operating expenses were $46.50 million, producing a six-month net loss of $39.66 million. The balance sheet shows total assets of $310.7 million, an accumulated deficit of $271.4 million and 74,262,990 common shares outstanding (per the filing).
Clinical progress reported: opening of Cohort 3 for [212Pb]VMT-α-NET (Cohort 2 had 46 patients treated), FDA "study may proceed" for PSV359 with two patients treated as of July 31, 2025, and Fast Track designation for [212Pb]VMT01. The company also reported recent patent grants and continued investments in manufacturing capacity.
Perspective Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and furnished that press release as Exhibit 99.1 to this Form 8-K. The filing also states the company posted an updated corporate presentation on its website and furnished that presentation as Exhibit 99.2. The 8-K clarifies that the information is "furnished" and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act.
The filing text does not include the actual financial figures or metrics; those details are contained in the referenced exhibits. This disclosure informs investors that quarter-end results and investor materials have been released, while the legal notice about furnishing limits incorporation and Section 18 liability.
Perspective Therapeutics (NYSE: CATX) announced significant developments in its clinical trials program on June 21, 2025. The company has received FDA alignment to open the third dosing cohort of its Phase 1/2a clinical trial for [212Pb]VMT-α-NET, targeting patients with unresectable or metastatic somatostatin receptor 2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies.
Additionally, the company presented findings from a dosimetry sub-study using [202Pb]VMT-α-NET as an imaging agent at the Society of Nuclear Medicine & Molecular Imaging 2025 Annual Meeting in New Orleans. This presentation demonstrates the company's progress in developing innovative imaging solutions for neuroendocrine tumor treatment.
The 8-K filing also notes that Perspective Therapeutics has updated its corporate presentation on June 23, 2025, suggesting potential strategic or operational updates to its business model and development pipeline.